Clinical Trials Logo

Clinical Trial Summary

The impact of the COVID-19 pandemic has heavily influenced routine medical care. In the first months of the pandemic, healthcare authorities restricted medical care to emergency procedures, postponing elective surgical activity. Conversely, screening programmes and planned examinations have been temporarily suspended or delayed. Gradually, elective surgery and clinical activities have resumed, thanks to the weakening of the pandemic, to a better organization of the healthcare systems and to the diffusion of COVID-19 vaccines. In the present study, we aim to evaluate the impact of the COVID-19 pandemic on surgery for thyroid carcinoma. Particularly, we aim to investigate whether the delay in operations, screening programmes, and planned examinations for patients under follow-up after thyroid surgery have led to an increased number of aggressive tumours. To evaluate this aspect, we aim to compare the patients who had undergone thyroidectomy for thyroid cancer before the COVID-19 pandemic (from February 2019 to February 2020), during the first phase of the pandemic (from March 2020 to September 2020), and after the first phase of the COVID-19 pandemic (from October 2020 to October 2021).


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05178186
Study type Interventional
Source University of Cagliari
Contact
Status Enrolling by invitation
Phase N/A
Start date January 1, 2022
Completion date March 30, 2022

See also
  Status Clinical Trial Phase
Completed NCT02658513 - Evaluation of Lancet Blood Sampling for Radioiodine Dosimetry in Thyroid Cancer
Withdrawn NCT01707056 - The Effect of Coffee on the Absorption of Thyroid Hormone in Patients With Thyroid Carcinoma N/A
Completed NCT00215605 - Study of XL184 (Cabozantinib) in Adults With Advanced Malignancies Phase 1
Recruiting NCT04327999 - Effect of Artificial Tears on Radioiodine Levels in the Nasolacrimal Duct System Phase 2
Completed NCT02194920 - Parathyroid Reimplantation in Forearm Subcutaneous Tissue During Thyroidectomy: a Simple Way to Avoid Ipoparathyroidism and Evaluate Graft Function N/A
Active, not recruiting NCT02145143 - Enhancing Radioiodine (RAI) Incorporation Into BRAF Mutant, RAI-Refractory Thyroid Cancers With the BRAF Inhibitor Vemurafenib: A Pilot Study N/A
Terminated NCT01865838 - A Study Into the Effect of Seprafilm in Open Total Thyroidectomy N/A
Recruiting NCT00749697 - Radioiodine Dosimetry Protocol for Thyroid Cancer Metastases N/A
Enrolling by invitation NCT04411290 - Malignancy Predictors, Bethesda and TI-RADS Scores Correlated With Final Histopathology in Thyroid Diseases
Completed NCT01813136 - Phase II Study of the Optimal Scheme of Administration of Pazopanib in Thyroid Carcinoma Phase 2
Active, not recruiting NCT02185560 - Prospective, Non-interventional, Post-authorization Safety Study That Includes All Patients Diagnosed as Unresectable Differentiated Thyroid Carcinoma and Treated With Sorafenib
Recruiting NCT04462471 - Vemurafenib Plus Copanlisib in Radioiodine-Refractory (RAIR) Thyroid Cancers Phase 1
Completed NCT01433809 - Biomarkers to Distinguish Benign From Malignant Thyroid Neoplasm N/A
Recruiting NCT00929318 - Influence of Thyroid Hormones on the Woundhealing Process N/A
Recruiting NCT02773667 - Renal Tracer Elimination in Thyroid Cancer Patients Treated With 131-Iodine
Completed NCT01013597 - Trial of LBH589 in Metastatic Thyroid Cancer Phase 2
Not yet recruiting NCT00993837 - Feasibility of Endoscopic Thyroidectomy for Thyroid Carcinoma N/A
Recruiting NCT03500666 - Comparative Study of Robot BABA Approach and Chest Breast Approach for Lateral Neck Dissection N/A
Completed NCT02614495 - Study of Sulfatinib in Treating Advanced Medullary Thyroid Carcinoma and Iodine-refractory Differentiated Thyroid Carcinoma Phase 2
Completed NCT01487057 - Lipid Metabolic Status in Thyroid Carcinoma N/A